Chimerix Company Overview
About Chimerix
Chimerix (NASDAQ:CMRX) is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for life-threatening diseases caused by viruses and cancer. With a commitment to innovation, Chimerix aims to improve outcomes for severely ill patients and their families by providing novel treatments. The company's pipeline is diversified, including antiviral compounds and new oncology therapies. Among its key projects is the development of brincidofovir, an antiviral intended for the treatment of smallpox, highlighting its dedication to addressing global health threats. Chimerix’s objective revolves around leveraging its proprietary technology to deliver first-in-class and best-in-class medicines, aiming to transform the therapeutic landscape for patients in dire need of effective treatments.
Snapshot
Operations
Products and/or services of Chimerix
- Developing antiviral and oncology medications aimed at treating viral infections and cancer.
- Focused on research and development of novel antiviral compounds.
- Offering contract development and manufacturing services.
- Advancing clinical studies for new drug candidates.
- Providing expertise in drug formulation and delivery technologies.
- Collaborating with other pharmaceutical companies for the development of combination therapies.
Chimerix executive team
- Mr. Michael T. Andriole M.B.A.CEO, President & Director
- Dr. Michael A. Alrutz J.D., Ph.D.Senior VP, General Counsel & Corporate Secretary
- Dr. Allen S. Melemed M.B.A., M.D.Chief Medical Officer
- Ms. Michelle LaSpalutoChief Financial Officer
- Mr. Thomas J. RigaChief Operating & Commercial Officer
- Mr. David Jakeman CPAVice President of Accounting & Finance
- Dr. Roy W. Ware M.B.A., Ph.D.Chief Manufacturing & Technology Officer
- Dr. Joshua E. Allen Ph.D.Chief Scientific Officer